Company profile
BioRay Laboratories (Shanghai Bangyao Biotechnology Co., Ltd.)
Privately held: no public share price (IMPORTANT -- distinct from the existing roster company_id 981 "BioRay Pharmaceutical Co." (Hangzhou-based, PAG-backed, focused on immune-mediated diseases like rheumatoid arthritis). "Bioray Laboratories" is a separate, Shanghai-based HSC/CAR-T cell-therapy company (Shanghai Bangyao Biotechnology, uses CRISPR-edited HSC/CAR-T for beta-thalassemia and B-cell lymphomas). Deliberately NOT resolved to company_id 981 despite the similar name -- confirmed private, not publicly traded. Sources: https://clinicaltrials.gov/study/NCT03492268 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | BCMACell therapy | Multiple Myeloma | |
| Preclinical | BCMACell therapy | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.